Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor purchased 22,026 shares of the stock in a transaction on Friday, March 28th. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the transaction, the chief executive officer now owns 59,383 shares of the company's stock, valued at approximately $133,017.92. The trade was a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Perspective Therapeutics Stock Performance
NYSE CATX traded down $0.16 during trading on Friday, reaching $1.80. The company's stock had a trading volume of 1,189,656 shares, compared to its average volume of 1,013,026. The firm has a 50 day moving average price of $2.77 and a 200 day moving average price of $5.91. Perspective Therapeutics, Inc. has a 12 month low of $1.79 and a 12 month high of $19.05.
Institutional Investors Weigh In On Perspective Therapeutics
Several institutional investors have recently made changes to their positions in CATX. Y Intercept Hong Kong Ltd bought a new stake in Perspective Therapeutics during the fourth quarter worth about $33,000. Aigen Investment Management LP acquired a new stake in Perspective Therapeutics during the 4th quarter worth approximately $34,000. National Bank of Canada FI lifted its holdings in Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after buying an additional 10,998 shares during the period. ProShare Advisors LLC lifted its stake in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth $51,000. 54.66% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently commented on CATX. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Finally, Wedbush reiterated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Perspective Therapeutics has an average rating of "Buy" and an average price target of $14.44.
Read Our Latest Stock Report on Perspective Therapeutics
About Perspective Therapeutics
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Articles
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
